Oncology outlook: ASX small caps driving innovation in cancer treatment скачать в хорошем качестве

Oncology outlook: ASX small caps driving innovation in cancer treatment

The global oncology drug market, valued at USD 231.56 billion in 2024, is expected to grow to USD 532.91 billion by 2031, driven by demand for targeted therapies, biomarker-based treatments, and immunotherapies. Several ASX-listed companies are contributing to this innovation: Arovella Therapeutics Ltd: Developing its invariant Natural Killer T (iNKT) cell therapy platform to treat blood cancers and solid tumours. Lead product ALA-101 uses CAR19-iNKT cells to target the CD19 antigen. The company recently raised $20 million to fund a phase 1 trial for CD19-positive blood cancers. Race Oncology Ltd: Focused on its lead asset, bisantrene, a small-molecule chemotherapeutic with reduced cardiotoxicity. A reformulated version, RC220, is being developed to meet unmet oncology needs. Imugene Ltd: Advancing immuno-oncology therapies, including azer-cel, an off-the-shelf CAR T therapy targeting CD19 for blood cancers, B-cell vaccine candidates, and CF33 oncolytic virotherapy, which combines engineered viruses with immunotherapies for solid tumours. Prescient Therapeutics Ltd: Developing personalised cancer treatments with technologies from institutions like Yale and Oxford. Lead drug PTX-100 has FDA Orphan Drug Designation for T-cell lymphomas. Its OmniCAR and CellPryme platforms enhance CAR-T therapies for improved efficacy and adaptability. These companies exemplify the growth and innovation occurring within the oncology sector. #ProactiveInvestors #ASX #OncologyMarket #ASXCompanies #ArovellaTherapeutics #RaceOncology #Imugene #PrescientTherapeutics #CancerResearch #ImmunoOncology #CellTherapy #TargetedTherapies #CAR_T #PersonalisedMedicine #CancerCare #BiotechNews #OncologyInnovation #GlobalHealthcare #ClinicalTrials #FDAApproval #SolidTumours #BloodCancers